PD-L1/TGF-β双功能抑制剂融合蛋白M7824研究进展

doi:10.3760/cma.j.issn.1673-422X.2019.05.006

摘要/Abstract

摘要： 随着程序性死亡蛋白-1（PD-1）及程序性死亡蛋白配体-1（PD-L1）抑制剂的发展，第二代联合免疫抑制剂应运而生。作为一种PD-L1/转化生长因子-β（TGF-β）双功能融合蛋白，M7824可在拮抗PD-L1通路的同时捕获TGF-β，有效增强免疫应答，减少免疫逃逸及耐药性的发生。该药物在多个临床前研究中取得显著疗效，然而其适应证、安全性、有效性仍需大型临床研究数据证实。

关键词: 重组融合蛋白质类, 转化生长因子β, PD-L1, M7824

Abstract: With the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, the second generation of combined immunosuppressive agents emerge as the times require. As a bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein, M7824 can antagonize PD-L1 pathway and trap TGF-β at the same time, which can effectively enhance the immune response and reduce the occurrence of immune escape and drug resistance. The drug has achieved remarkable results in many preclinical studies, however, the indications, safety and efficacy still need to be confirmed by large-scale clinical research data.

Key words: Recombinant fusion proteins, Transforming growth factor β, PD-L1, M7824

胡梦雪，许斌，于金明，宋启斌. PD-L1/TGF-β双功能抑制剂融合蛋白M7824研究进展[J]. 国际肿瘤学杂志, 2019, 46(5): 281-284.

Hu Mengxue, Xu Bin, Yu Jinming, Song Qibin. Advances of bifunctional anti-PD-L1/TGF-β fusion protein M7824[J]. Journal of International Oncology, 2019, 46(5): 281-284.

参考文献

［1］ Guo L, Zhang Y, Zhang L, et al. MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer［J］. Tumour Biol, 2016, 37(1): 115-125. DOI: 10.1007/s13277-015-4374-2. ［2］ Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease［J］. Nat Rev Drug Discov, 2012, 11(10): 790-811. DOI: 10.1038/nrd3810. ［3］ Ravi R, Noonan KA, Pham V, et al. Bifunctional immune checkpointtargeted antibodyligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy［J］. Nat Commun, 2018, 9(1): 741. DOI: 10.1038/s41467-017-02696-6. ［4］ Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumourassociated macrophages inhibits phagocytosis and tumour immunity［J］. Nature, 2017, 545(7655): 495-499. DOI: 10.1038/nature22396. ［5］ Moustakas A, Heldin CH. Mechanisms of TGFβ-induced epithelialmesenchymal transition［J］. J Clin Med, 2016, 5(7). pii: E63. DOI: 10.3390/jcm5070063. ［6］ Bai WD, Ye XM, Zhang MY, et al. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer［J］. Int J Cancer, 2014, 135(6): 1356-1368. DOI: 10.1002/ijc.28782. ［7］ Lin RL, Zhao LJ. Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer［J］. Cancer Biol Med, 2015, 12(4): 385-393. DOI: 10.7497/j.issn.20953941.2015.0015. ［8］ Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells［J］. Nature, 2018, 554(7693): 544-548. DOI: 10.1038/nature25501. ［9］ Duan J, Liu X, Chen H, et al. Impact of PDL1, transforming growth factorβ expression and tumor-infiltrating CD8⁺T cells on clinical outcome of patients with advanced thymic epithelial tumors［J］. Thorac Cancer, 2018, 9(11): 1341-1353. DOI: 10.1111/1759-7714.12826. ［10］ Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity［J］. Immunol Rev, 2010, 236: 219-242. DOI: 10.1111/j.1600-065x.2010.00923.x. ［11］ Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells［J］. J Exp Med, 2009, 206(13): 3015-3029. DOI: 10.1084/jem.20090847. ［12］ Morikawa M, Derynck R, Miyazono K. TGFβ and the TGFβ family: contextdependent roles in cell and tissue physiology［J］. Cold Spring Harb Perspect Biol, 2016, 8(5). pii: a021873. DOI: 10.1101/cshperspect.a021873. ［13］ Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β［J］. Sci Transl Med, 2018, 10(424). pii: eaan5488. DOI: 10.1126/scitranslmed.aan5488. ［14］ Knudson KM, Hicks KC, Luo X, et al. M7824, a novel bifunctional antiPD-L1/TGFβ Trap fusion protein, promotes antitumor efficacy as monotherapy and in combination with vaccine［J］. OncoImmunology, 2018, 7(5): e1426519. DOI: 10.1080/2162402X.2018.1426519. ［15］ Jochems C, Tritsch SR, Pellom ST, et al. Analyses of functions of an antiPD-L1/TGFβR2 bispecific fusion protein (M7824)［J］. Oncotarget, 2017, 8(43): 75217-75231. DOI: 10.18632/oncotarget.20680. ［16］ Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors［J］. Clin Cancer Res, 2018, 24(6): 1287-1295. DOI: 10.1158/1078-0432.CCR-17-2653. ［17］ Dovedi SJ, Adlard AL, LipowskaBhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade［J］. Cancer Res, 2014, 74(19): 5458-5468. DOI: 10.1158/0008-5472.CAN-14-1258. ［18］ Grenga I, Donahue RN, Gargulak ML, et al. AntiPDL1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immunemediated recognition and lysis［J］. Urol Oncol, 2018, 36(3): 93. e1-e93. e11. DOI: 10.1016/j.urolonc.2017.09.027. ［19］ David JM, Dominguez C, McCampbell KK, et al. A novel bifunctional antiPD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells［J］. Oncoimmunology, 2017, 6(10): e1349589. DOI: 10.1080/2162402X.2017.1349589. ［20］ Liu L, Liu X, Ren X, et al. Smad2 and Smad3 have differential sensitivity in relaying TGFβ signaling and inversely regulate early lineage specification［J］. Sci Rep, 2016, 6: 21602. DOI: 10.1038/srep21602. ［21］ Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as firstline treatment in cisplatinineligible patients with locally advanced and metastatic urothelial carcinoma: a singlearm, multicentre, phase 2 trial［J］. Lancet, 2017, 389(10064): 67-76. DOI: 10.1016/S0140-6736(16)32455-2. ［22］ Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinumtreated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial［J］. Lancet, 2018, 391(10122): 748-757. DOI: 10.1016/S0140-6736(17)33297-X. ［23］ Terabe M, Robertson FC, Clark K, et al. Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy［J］. Oncoimmunology, 2017, 6(5): e1308616. DOI: 10.1080/2162402X.2017.1308616. ［24］ Park BV, Freeman ZT, Ghasemzadeh A, et al. TGF-β1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer［J］. Cancer Discov, 2016, 6(12): 1366-1381. DOI: 10.1158/2159-8290.CD-15-1347. ［25］ Luis G, Tae K, David VB, et al. Results from a secondline (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctiona fusion protein targeting TGF-β and PD-L1［J］. J Clin Oncol, 2018, 36 (15_Suppl): 9017. DOI: 10.1200/JCO.2018.36.15_suppl.9017. ［26］ Julius S, Margaret GM, Jason R, et al. Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers［J］. J Clin Oncol, 2018, 36 (15_Suppl): 3007. DOI: 10.1200/JCO.2018.36.15_suppl.3007. ［27］ Yoo C, oh DY, Choi HJ, et al. AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype［J］. ESMO, 2019, In press. DOI: 10.21037/hbsn.2019.AB053.

[1]	王悦, 呼群, 侯英伟. 表观遗传修饰对肿瘤PD-L1表达调控的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 345-348.
[2]	宁婷婷, 胡钦勇. 二甲双胍在肿瘤免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 292-295.
[3]	丁心静, 丁江华. 皮肤免疫相关不良事件与PD-1/PD-L1抑制剂临床疗效相关性的研究进展[J]. 国际肿瘤学杂志, 2022, 49(4): 225-228.
[4]	谢红霞, 左金辉, 廖冬颖, 邓仁芬, 姚杨, 贾英杰, 李小江, 孔凡铭. PD-L1抑制剂在非小细胞肺癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 111-115.
[5]	李宁, 张玢琪. 免疫检查点抑制剂在子宫内膜癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(2): 125-128.
[6]	欧惠仪, 王越, 彭承宏. PD-L1与Treg在肿瘤免疫及治疗中的相关性[J]. 国际肿瘤学杂志, 2021, 48(6): 350-353.
[7]	丁艳, 汪红艳. PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2021, 48(2): 113-116.
[8]	赵丽丽, 赵文文, 冯青青, 赵文飞, 张雪, 井文君, 魏红梅. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2021, 48(12): 705-710.
[9]	曹纯, 何文琪, 晏军. 免疫检查点抑制剂在小细胞肺癌治疗中的应用[J]. 国际肿瘤学杂志, 2021, 48(12): 747-750.
[10]	薛晨, 赵月, 石光, 唐艳. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(5): 312-315.
[11]	徐阳涛, 陈彪, 何晓琴, 徐细明. 免疫治疗超进展的研究进展[J]. 国际肿瘤学杂志, 2020, 47(12): 737-740.
[12]	宋博, 邬明歆, 贾英杰, 李小江. PD-1/PD-L1抑制剂引起免疫相关性肺炎的研究进展[J]. 国际肿瘤学杂志, 2020, 47(10): 627-629.
[13]	张李卓, 钱杨洋, 郑国湾, 葛明华. PD-1/PD-L1在肿瘤中的机制研究及其在甲状腺癌中的诊治价值[J]. 国际肿瘤学杂志, 2020, 47(1): 39-42.
[14]	白馨雅, 张金梦, 孙洋, 安永恒. 免疫检查点抑制剂在晚期非小细胞肺癌综合治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(8): 500-504.
[15]	胡耿维1, 张莹2, 吴志浩3. 免疫检测点PD-1/PD-L1的机制研究及免疫治疗[J]. 国际肿瘤学杂志, 2019, 46(2): 87-90.